NCT05111795COMPLETEDanonymous

Holmium-166 Retrospective Collection of Real-World Data

Sponsor

Source record

Terumo Europe N.V.

Phase

Source record

Not classified

Modality

AI-normalized

RNA therapy

Target

AI-normalized

Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres

Indication / condition

AI-normalized

Hepatocellular Carcinoma

Intervention

Source record

Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres

Related intelligence directories

Indication directory: Hepatocellular Carcinoma Modality directory: RNA therapy Target directory: Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres

Source & freshness

Source record

NCT ID

NCT05111795

Original source

ClinicalTrials.gov

Source last updated

Detailed source ingestion pending.

Ingested at

Jun 22, 2026

Internal sync

Jun 22, 2026

Model version

trialsignal-ai-v1

Normalized confidence

96%

Validation status

validated

Open original registry record

View original source fields

NCT ID

NCT05111795

Title

Holmium-166 Retrospective Collection of Real-World Data

Sponsor

Terumo Europe N.V.

Status

COMPLETED

Phase

Detailed source ingestion pending

Condition raw

Hepatocellular Carcinoma, Metastatic Cancer

Condition normalized

Hepatocellular Carcinoma, Metastatic Cancer

Modality raw

RNA therapy

Modality normalized

RNA therapy

Target raw

Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres

Target normalized

Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres

Interventions

Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres

Public preview

Source record

The primary objective of the study is to further describe the general safety and clinical performance of QuiremSpheresTM Holmium-166 Microspheres and QuiremScoutTM Holmium-166 Microspheres in a real-world post-market setting, with specific attention to outcomes per tumor origin.

AI-generated analysis supports research triage only. Verify source records, publications, sponsor disclosures and IP databases before making diligence decisions. Model: trialsignal-ai-v1.

Report access

Create an account to unlock this report

Choose the access model that matches the job: one urgent report, reusable credits for project work, or unlimited monthly access with AI and folders.

Early access offer

Subscribe with code FOUNDERS5 for a 5-day premium trial.

Full protocol, outcomes, eligibility, contacts and results sections

Patent/IP landscape with verified records when available

Board-ready PDF export with source provenance

Save to folders and synthesize multiple assets in premium workspace

Create account

Create a free account first, then unlock a single report, buy credits or subscribe.

TrialSignal

Clinical trial intelligence report

Holmium-166 Retrospective Collection of Real-World Data

Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.

Generated

Jun 24, 2026

Report code

NCT05111795-Jun 24, 2026

NCT ID

NCT05111795

Status

COMPLETED

Phase

N/A

Sponsor

Terumo Europe N.V.

Executive brief

Investment-Ready Snapshot

Source & freshness

Provenance

SourceClinicalTrials.gov

Source updatedDetailed source ingestion pending.

Internal syncJun 22, 2026

Model versiontrialsignal-ai-v1

https://clinicaltrials.gov/study/NCT05111795

Indication

Hepatocellular Carcinoma

Modality

RNA therapy

Target

Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres

Intervention

Selective Internal Radiation Therapy with QuiremSpheresTM Holmium-166 Microspheres

Source record

Protocol Description

Detailed source ingestion pending.

Source record

Outcome Measures

Detailed source ingestion pending.

Source record

Eligibility

Detailed source ingestion pending.

AI analysis

Known Results And Readout Context

Detailed source ingestion pending.

IP intelligence

Patent And IP Landscape

Detailed source ingestion pending.

Source record

Contacts

Detailed source ingestion pending.